TidalSense team. Image Credits:<\/strong> TidalSense<\/p>\n<\/div>\n

In an interview with TechCrunch, co-founder Dr. Ameera Patel (pictured, right), CEO of TidalSense and an asthma sufferer herself, told me: \u201cThis hardware has been developed for eight years. There\u2019s several patents on it now. The sensor measures every single molecule of carbon dioxide that comes out of your lungs. What we\u2019ve discovered with collecting all this data is that we can tell really sensitively when your lungs are getting worse.\u201d<\/p>\n

She says the problem is that people don\u2019t know when they\u2019re symptomatic: \u201cThey don\u2019t know when they\u2019re getting sicker. This device will tell me immediately and I\u2019ll know to increase my inhalers. It\u2019s the difference between being able to manage your symptoms and suddenly landing in hospital because you had no data on the lead-up to things getting worse.\u201d<\/p>\n

The company says it has benchmarked the device on over 1,000 patients, collecting over 2.3 million breaths from patients through clinical studies and trials.<\/p>\n

\u201cWe\u2019re getting really, really high accuracies on diagnosing COPD because fundamentally, in COPD, your lung structure changes. From the data we built very accurate diagnostic tests, which we\u2019re looking to commercialize with the funding,\u201d Patel added.<\/p>\n

Tim Rea, head of Early Stage Investments at BGF, commented in a statement that \u201cthis solution is a prime example of where advanced\u00a0 machine learning techniques can be applied to deliver faster diagnostics, greater efficiencies and better patient outcomes.\u201d<\/p>\n<\/p><\/div>\n

<\/br><\/br><\/br><\/p>\n